Photoreceptor Cell Therapy to Treat Advanced Retinal Degeneration

Sight is frequently ranked our most precious sense, the one we fear losing the most. For patients with sight-loss of known genetic cause, gene therapy is beginning to offer significant promise. However, for most patients there is no treatment that can reverse blindness once photoreceptor degeneration has occurred. Photoreceptor replacement therapy, either as cell suspension or tissue grafts, offers the opportunity to restore sight by replacing lost cells and is gaining traction as a valid disease-agnostic therapeutic approach for the treatment of advanced retinal degeneration.

Pearson et al. have previously developed protocols for the generation of rod and cone photoreceptors from human pluripotent stem cells (hPSC) and here show that hPSC-derived cone photoreceptors can functionally integrate into two different mouse models of end stage disease. They show that the recipient retina undergoes significant remodelling in response to human cones and that the transplanted human cones can drive retinal function across a range of physiologically relevant light levels. Using Striatech’s OptoDrum, Pearson et al. further show that transplanted animals also exhibit light-evoked optomotor head tracking behaviour. Together, these observations provide support for human cone transplantation as a disease-agnostic therapy for advanced retinal dystrophies.